Recombinant FOLR1 (Mirvetuximab Biosimilar) anticorps
Aperçu rapide pour Recombinant FOLR1 (Mirvetuximab Biosimilar) anticorps (ABIN7795120)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Mirvetuximab Biosimilar, Human FOLR1 Monoclonal Antibody
-
Attributs du produit
- What is Mirvetuximab biosimilar research grade? Mirvetuximab biosimilar uses the same protein sequences as the therapeutic antibody Mirvetuximab. Mirvetuximab soravtansine is used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha (FRa)-directed antibody and microtubule inhibitor conjugate.
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- Human FOLR1
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- FOLR1 (Mirvetuximab Biosimilar)
-
Autre désignation
- Mirvetuximab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-